Cysteamine as a New Skin Depigmenting Agent
Join our referral program. Try out cysteamine cream in your clinic.
Cysteamine hydrochloride (β-Mercaptoethylamine hydrochloride)
Novel Discovery in Skin Hyperpigmentation Treatment
Cysteamine is the simplest aminothiol biosynthesised in the human cells. It is the product of degradation of the essential amino-acid L-cysteine and is synthesized by human body cells during the co-enzyme A metabolism cycle. Cysteamine promotes the transport of L-cysteine into cells, that can be further used to synthesize glutathione, which is one of the most potent intracellular antioxidants.
Cysteamine has FDA approval for human use. It has a long history of oral use in human, for the treatment of cystinosis, and has potential for the treatment of radiation sickness, neurodegenerative diseases and cancer prevention.
Cysteamine has been previously shown by independent researchers to have significant depigmenting activity in in-vitro and animal studies. Cysteamine was never managed to be formulated into a topical product due to its fast oxidation leading to a very bad odor. Our new technology has enabled us to stabilize cysteamine and significantly reduce its odor in cream conditions for the first time.
Cysteamine Cream, Higher Depigmenting Efficacy Compared To Hydroquinone
Cysteamine cream has been recently introduced as a treatment for skin hyperpigmentary disorders. Well controlled-Clinical studies have consistently confirmed its efficacy in melasma. Pigment cell researchers have concluded in the higher depigmenting efficacy of cysteamine compared to hydroquinone.
Kasraee B. "Deodorized cysteamine* as a depigmenting agent for the treatment of melasma." Pigment Cell Melanoma Research. 2017;30:e27–e137
Farshi S. et al. "Efficacy of Cysteamine Cream in the treatment of melasma." Journal of Dermatological Treatment July 2017
Mansouri P. et al. “Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial.” British Journal of Dermatology (2015) 173, pp 209-217
Hsu C. et al. "Cysteamine cream as a new skin depigmenting product." Journal of the American Academy of Dermatology (2013) 68:4-1 AB189
Cysteamine Cream, Superior Benefit/Risk Ratio Compared To Hydroquinone And Other Alternatives
- Goorochurn R. "Cysteamine as the new treatment of human hyperpigmentation disorders", EADV 2017, Septembre 2017
Known skin depigmenting molecules such as hydroquinone and kojic acid have been recently shown to exhibit mutagenic and carcinogenic effects and have been restricted by the FDA and European authorities. Recently, Cysteamine cream has been introduced as a treatment for skin hyperpigmentary diseases. Several well-controlled clinical studies have shown its efficacy in melasma. Cysteamine is shown not to be mutagenic or carcinogenic and interestingly shows an anti-mutagenic, anti-cancer and anti-melanoma effect demonstrated in in vitro and in vivo models. Taken together cysteamine has a superior benefit/risk ratio compared to other alternatives and is considered as the new standard treatment for hyperpigmentation disorders.
Referral Program Registration
Our Patient Care Program offers long-term follow up for patients with melasma. Some of our patients are looking for local referral to clinics who could help them with their skin conditions. We would like to refer them to well reputated clinics.
Orders for Professionals
Discover the latest biological depigmenting technology.